102.30
0.05 (0.05%)
| Penutupan Terdahulu | 102.25 |
| Buka | 102.25 |
| Jumlah Dagangan | 1,794,994 |
| Purata Dagangan (3B) | 5,501,872 |
| Modal Pasaran | 19,428,497,408 |
| Harga / Pendapatan (P/E Ke hadapan) | 188.68 |
| Harga / Jualan (P/S) | 6.03 |
| Harga / Buku (P/B) | 8.25 |
| Julat 52 Minggu |
| Margin Keuntungan | -36.06% |
| Margin Operasi (TTM) | -11.53% |
| EPS Cair (TTM) | -5.53 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 10.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 105.93% |
| Nisbah Semasa (MRQ) | 2.73 |
| Aliran Tunai Operasi (OCF TTM) | 323.66 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 163.08 M |
| Pulangan Atas Aset (ROA TTM) | -1.83% |
| Pulangan Atas Ekuiti (ROE TTM) | -36.89% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Exact Sciences Corporation | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | 0.0 |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
|
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.92% |
| % Dimiliki oleh Institusi | 98.89% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 105.00 (Mizuho, 2.64%) | Pegang |
| 105.00 (Evercore ISI Group, 2.64%) | Pegang | |
| Median | 105.00 (2.64%) | |
| Purata | 105.00 (2.64%) | |
| Jumlah | 2 Pegang | |
| Harga Purata @ Panggilan | 101.98 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Mizuho | 20 Jan 2026 | 105.00 (2.64%) | Pegang | 102.35 |
| Evercore ISI Group | 05 Jan 2026 | 105.00 (2.64%) | Pegang | 101.61 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CONDELLA SARAH | - | 103.38 | -1,913 | -197,766 |
| CONROY KEVIN T | 103.27 | 103.33 | -25,022 | -2,587,543 |
| Jumlah Keseluruhan Kuantiti Bersih | -26,935 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,785,309 | |||
| Purata Pembelian Keseluruhan ($) | 103.27 | |||
| Purata Jualan Keseluruhan ($) | 103.34 | |||
| Julat Insider ($) | ||||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| CONDELLA SARAH | Pegawai | 27 Feb 2026 | Dibuang (-) | 1,913 | 103.38 | 197,766 |
| CONDELLA SARAH | Pegawai | 27 Feb 2026 | Pelaksanaan pilihan | 3,900 | - | - |
| CONROY KEVIN T | Pegawai | 27 Feb 2026 | Dibuang (-) | 32,007 | 103.38 | 3,308,884 |
| CONROY KEVIN T | Pegawai | 27 Feb 2026 | Pelaksanaan pilihan | 68,097 | - | - |
| CONROY KEVIN T | Pegawai | 25 Feb 2026 | Diperolehi (+) | 13,181 | 103.27 | 1,361,202 |
| CONROY KEVIN T | Pegawai | 25 Feb 2026 | Dibuang (-) | 6,196 | 103.27 | 639,861 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Feb 2026 | Pengumuman | Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests |
| 03 Feb 2026 | Pengumuman | Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide |
| 11 Dec 2025 | Pengumuman | Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |